search
Back to results

Autologous Bone Marrow For Lower Extremity Ischemia Treating

Primary Purpose

Lower Extremity Ischemia

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Bone marrow aspiration, injection of cells
Bone marrow aspiration , injection of isolated CD 133+ cells
Bone marrow aspiration, injection of saline
Sponsored by
Clinical Center of Cellular Technologies, Russia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lower Extremity Ischemia focused on measuring lower extremity ischemia, Bone marrow, Progenitor cells, Neoangiogenesis

Eligibility Criteria

39 Years - 70 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification)
  • a painless walking distance of 10-50 m
  • pulse absence on аа. dorsalis pedis, tibialis posterior, poplitea
  • absence of a ischemia in a rest and necrotic changes
  • mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries) according to an angiography that testifies to impossibility of reconstructive operation performance
  • patients after a lumbar sympathectomy and a tibial bone osteoperforations executed previously
  • heavy smokers

Exclusion Criteria:

  • insulin depended diabetes
  • myocardial infarction or a stroke within last year
  • an idiopathic hypertensia III stage
  • anaemia and other diseases of blood
  • decompensation of the chronic diseases which are contraindications to any surgical operation
  • HIV infection
  • a virus hepatitis
  • oncologic diseases
  • chemotherapy in the anamnesis

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    CD133

    TNC

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Increasing of painless walking distance

    Secondary Outcome Measures

    Full Information

    First Posted
    September 9, 2008
    Last Updated
    September 15, 2008
    Sponsor
    Clinical Center of Cellular Technologies, Russia
    Collaborators
    Samara State Medical University, Regional hospital of Samara
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00753025
    Brief Title
    Autologous Bone Marrow For Lower Extremity Ischemia Treating
    Official Title
    Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2008
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2006 (undefined)
    Primary Completion Date
    June 2007 (Actual)
    Study Completion Date
    February 2008 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Clinical Center of Cellular Technologies, Russia
    Collaborators
    Samara State Medical University, Regional hospital of Samara

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to determine whether autologous bone marrow derived cells and isolated CD133+ fraction are effective in the treatment limb ischemia
    Detailed Description
    The number of patients with low limb obliterating atherosclerosis steadily grows and compounds more than 20-25 % from all kinds of a cardiovascular pathology. At conservation of this tendency to 2020 the amputation percentage executed due to vessel diseases, can reach 45 %. Hemodynamics improvement in an extremity by surgery is possible at 40 - 70 % of patients even with the widespread and plural lesion of arteries, but results are not always satisfactory. The most actual is the problem of angiosurgical help to patients with distal forms of arterial occlusions, due to the difficulty or impossibility performing reconstructive interventions. In these cases the operations of an indirect revascularization referred on stimulation of a collateral blood flow are carried out. However, despite the reached successes, in some cases results of such interventions do not give desirable effect, search of new methods of treatment therefore is necessary. To date the most perspective methods of neoangiogenesis stimulation are a cellular therapy and gene-engineering technologies. Experimental researches on a model of local limb ischemia showed possibility of use of various cells for neoangiogenesis stimulation. A number of clinical researches at patients with obliterating limb diseases has shown efficacy of cellular therapy even at a critical ischemia. However randomized, the placebo-controlled researches based on principles of evidence based medicine while it is not enough for the convincing conclusions.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lower Extremity Ischemia
    Keywords
    lower extremity ischemia, Bone marrow, Progenitor cells, Neoangiogenesis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    42 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    CD133
    Arm Type
    Experimental
    Arm Title
    TNC
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Procedure
    Intervention Name(s)
    Bone marrow aspiration, injection of cells
    Intervention Description
    Bone marrow is aspirated at patients in all arms. Arm "TNC" receives injection of total nucleated cells into ischemic muscle
    Intervention Type
    Procedure
    Intervention Name(s)
    Bone marrow aspiration , injection of isolated CD 133+ cells
    Intervention Description
    arm "CD133" receives injection of isolated CD 133+ cells
    Intervention Type
    Procedure
    Intervention Name(s)
    Bone marrow aspiration, injection of saline
    Intervention Description
    arm "placebo" receives injection of saline
    Primary Outcome Measure Information:
    Title
    Increasing of painless walking distance
    Time Frame
    Within the first 30 days, 6 months and 12 months after injection

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    39 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification) a painless walking distance of 10-50 m pulse absence on аа. dorsalis pedis, tibialis posterior, poplitea absence of a ischemia in a rest and necrotic changes mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries) according to an angiography that testifies to impossibility of reconstructive operation performance patients after a lumbar sympathectomy and a tibial bone osteoperforations executed previously heavy smokers Exclusion Criteria: insulin depended diabetes myocardial infarction or a stroke within last year an idiopathic hypertensia III stage anaemia and other diseases of blood decompensation of the chronic diseases which are contraindications to any surgical operation HIV infection a virus hepatitis oncologic diseases chemotherapy in the anamnesis
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Olga Tyumina, PhD
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Autologous Bone Marrow For Lower Extremity Ischemia Treating

    We'll reach out to this number within 24 hrs